Doublecortin-like kinase 1 (DCLK1) is a microtubuleassociated protein that plays key roles in the regulation of neural cell differentiation, migration, and apoptosis during embryonic development (1, 2) . Accumulating evidence suggests that DCLK1 is a marker of intestinal and pancreatic stem cells and cancer stem cells; thus, it is attracting attention from both gastroenterologists and oncologists (3) (4) (5) (6) . The function of DCLK1 is not fully understood; however, at minimum, we know that this kinase induces epithelialmesenchymal transition (EMT), which supports the stemness of normal and neoplastic stem cells. Regarding mechanism of the DCLK1-induced EMT, involvement of specific microRNA-dependent upregulation of c-MYC, KRAS, and Notch1 expressions was demonstrated in pancreatic and colon cancer cells (7, 8) . Furthermore, a recent study has strengthened the evidence by shedding light on upregulation the EMT regulator SLUG by DCLK1 that resulted in increased cell migration ability (9) .
The location of and markers for adult pancreatic progenitor cells have long been debated. Westphalen et al. have recently demonstrated in their elegant lineagetracing study that DCLK1 labeled a rare population of long-lived, quiescent pancreatic progenitor cells that were necessary for pancreatic regeneration following injury and chronic inflammation (6) . Of interest, these quiescent DCLK1 + cells did not contribute to carcinogenesis even in the setting of KRAS mutation; however, experimental pancreatitis converted the KRAS-mutated DCLK1 + cells into potent cancer-initiating cells. A similar oncogenic role of DCLK1, activated by tissue injury, was also exhibited in colorectal cancer (10) . Despite such emerging recognized roles of DCLK1 in the stem cell milieu, why the neural stem/progenitor marker DCLK1 universally labels stem/ progenitors of non-neural organs, including the pancreas and colorectum, has not been eagerly discussed. Because DCLK1 was clearly expressed in both neuroblastoma and melanoma cells (Figure 1) (11) , which are derived from neural crest cells (NCCs) (12, 13) , it is speculated that DCLK1 + stem/progenitors in various organs originate from a neural-crest-derived cell population. Indeed, these tumors are clinically aggressive and metastatic, exhibiting increased migratory potential similar to NCCs. Neuroendocrine tumors (NETs), which robustly express DCLK1 (9) , are also known to be highly metastatic. Thus, DCLK1 positivity Editorial Pancreatic DCLK1 marks quiescent but oncogenic progenitors: a possible link to neuroendocrine tumors may be the key to understanding the tumor-cell behaviors of highly metastatic tumors, including NETs, neuroblastomas, and melanomas. SLUG, a crucial EMT regulator downstream of DCLK1, is expressed in all three tumor cell types described above (Figure 1) . Because SLUG is also an inevitable driver of EMT in NCCs (14), it is suggested that the high metastatic potential of DCLK1 + tumor cells may be attributable to their common cell origin, i.e., the neural crest. Thus, an examination on whether DCLK1 is expressed in NCCs and regulates their migration ability is required. Additionally, a lineage-tracing study focusing on NCCs would address the neural crest's involvement in the development and maintenance of quiescent and long-lived stem/progenitor cells in adult organs and cancers.
